Home
Scholarly Works
REACH-3 trial design: A Phase 3, Randomized Study...
Conference

REACH-3 trial design: A Phase 3, Randomized Study to Assess Ruxolitinib over BAT in Patients with Corticosteroid-Refractory Chronic Graft-versus-Host Disease Post Allo-HSCT

Authors

Zeiser R; Ram R; Foley SR; Yeshurun M; Locatelli F; Gadbaw B; Atienza E; Hollaender N; Teshima T

Volume

53

Pagination

pp. 444-446

Publisher

NATURE PUBLISHING GROUP

Publication Date

September 1, 2018

Name of conference

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT)

Conference place

Lisbon, PORTUGAL

Conference start date

March 18, 2018

Conference end date

March 21, 2018

Conference proceedings

BONE MARROW TRANSPLANTATION

ISSN

0268-3369

Contact the Experts team